ArticleBMC genomics2014
Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines.
Article in BMC genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Genetic modifiers of frequent vaso-occlusive hospitalizations among individuals with sickle cell disease (SCD).Annals of hematology · 2025Article
- Biobanks in chronic disease management: A comprehensive review of strategies, challenges, and future directions.Heliyon · 2024Review
- Preclinical-to-clinical Anti-cancer Drug Response Prediction and Biomarker Identification Using TINDL.Genomics, proteomics & bioinformatics · 2023Article
- Impaired Blastocyst Formation inInternational journal of molecular sciences · 2023Article
- Article
- Systematic evaluation of the effects of genetic variants on PIWI-interacting RNA expression across 33 cancer types.Nucleic acids research · 2021Article
- Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer.Pharmacogenomics · 2020Article
- Exploring predictive biomarkers from clinical genome-wide association studies via multidimensional hierarchical mixture models.European journal of human genetics : EJHG · 2019Article
- Genome-wide association analysis identifies SNPs predictive ofOncotarget · 2018Article
- LNX1/LNX2 proteins: functions in neuronal signalling and beyond.Neuronal signaling · 2018Review
- Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs inFrontiers in pharmacology · 2018Article
- Clinical validation of genetic variants associated withOncotarget · 2017Article
- Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.Pharmacogenetics and genomics · 2016Article
- Computational discovery of transcription factors associated with drug response.The pharmacogenomics journal · 2016Article
- Differential distribution improves gene selection stability and has competitive classification performance for patient survival.Nucleic acids research · 2016Article
- Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations.Pharmacogenomics · 2015Article
- In vitro human cell line models to predict clinical response to anticancer drugs.Pharmacogenomics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTwo cytidine analogues, gemcitabine and cytosine arabinoside (AraC), are widely used in the treatment of a variety of cancers with a large individual variation in response. To identify potential genetic biomarkers associated with response to these two drugs, we used a human lymphoblastoid cell line (LCL) model system with extensive genomic data, including 1.3 million SNPs and 54,000 basal expression probesets to perform genome-wide association studies (GWAS) with gemcitabine and AraC IC50 values.
resultsWe identified 11 and 27 SNP loci significantly associated with gemcitabine and AraC IC50 values, respectively. Eleven candidate genes were functionally validated using siRNA knockdown approach in multiple cancer cell lines. We also characterized the potential mechanisms of genes by determining their influence on the activity of 10 cancer-related signaling pathways using reporter gene assays. Most SNPs regulated gene expression in a trans manner, except 7 SNPs in the PIGB gene that were significantly associated with both the expression of PIGB and gemcitabine cytotoxicity.
conclusionThese results suggest that genetic variation might contribute to drug response via either cis- or trans- regulation of gene expression. GWAS analysis followed by functional pharmacogenomics studies might help identify novel biomarkers contributing to variation in response to these two drugs and enhance our understanding of underlying mechanisms of drug action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.